UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring

British journal of cancer, 2009-03, Vol.100 (5), p.684-692

2009

Volltextzugriff (PDF)

Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer

British journal of cancer, 2004-08, Vol.91 (4), p.639-643

2004

Volltextzugriff (PDF)

Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial

European journal of cancer (1990), 2018-11, Vol.104, p.160-168

2018

Volltextzugriff (PDF)

The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage

British journal of cancer, 2009-08, Vol.101 (4), p.582-588

2009

Volltextzugriff (PDF)

Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue

British journal of haematology, 2000-08, Vol.110 (2), p.292-299

2000

Volltextzugriff (PDF)

tAnGo : a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation

British journal of cancer, 2008-08, Vol.99 (4), p.597-603

2008

Volltextzugriff (PDF)

A phase II trial of low-dose estradiol in postmenopausal women with advanced breast cancer and acquired resistance to aromatase inhibition

European journal of cancer (1990), 2015-12, Vol.51 (18), p.2725-2731

2015

Volltextzugriff (PDF)

FULVESTRANT: A REVIEW OF ITS DEVELOPMENT, PRE‐CLINICAL AND CLINICAL DATA

International journal of clinical practice (Esher), 2002-05, Vol.56 (4), p.305-309

Wardley, AM

2002

Volltextzugriff (PDF)

The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone

British journal of cancer, 1998-09, Vol.78 (6), p.774-776

1998

Volltextzugriff (PDF)

114PThe incidence of metastases detected on a staging CT scan prior to neoadjuvant chemotherapy in early stage breast cancer

Annals of oncology, 2019-05, Vol.30 (Supplement_3)

2019

Volltextzugriff (PDF)

The incidence of metastases detected on a staging CT scan prior to neoadjuvant chemotherapy in early stage breast cancer

Annals of oncology, 2019-05, Vol.30, p.iii35-iii36

2019

Volltextzugriff (PDF)

198TiPA randomized, double-blinded, controlled study of tucatinib (ONT-380) vs placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB)

Annals of oncology, 2019-05, Vol.30 (Supplement_3)

2019

Volltextzugriff (PDF)

A quantitative histometric murine in vivo model of radiation-induced oral mucositis

Archives of oral biology, 1998-07, Vol.43 (7), p.567-577

1998

Volltextzugriff (PDF)

A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB)

Annals of oncology, 2019-05, Vol.30, p.iii63-iii64

2019

Volltextzugriff (PDF)

LBA23MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer (ABC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Fatal Candida tropicalis fungaemia in a leukaemic patient receiving fluconazole prophylaxis

The Journal of infection, 1996-07, Vol.33 (1), p.43-45

1996

Volltextzugriff (PDF)

314PNext-generation DNA sequencing (NGS) results for tumours from phase II ABRAZO study of talazoparib after platinum or cytotoxic non-platinum regimens in patients (pts) with advanced breast cancer (ABC) and germline BRCA1/2 (gBRCA) mutations

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Re: Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

JNCI : Journal of the National Cancer Institute, 2009-12, Vol.101 (24), p.1730-1730

2009

Volltextzugriff (PDF)

Abstract P6-17-01: Withdrawn

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P6-P6-17-01

2019

Volltextzugriff (PDF)

Polymorphisms of the aromatase gene (CYP19A1) and benefit of aromatase inhibitors (AIs) in metastatic breast cancer (mBC) patients

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.608-608

2011

Volltextzugriff (PDF)

Phase II data for entinostat, a class 1 selective histone deacetylase inhibitor, in patients whose breast cancer is progressing on aromatase inhibitor therapy

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.1052-1052

2010

Volltextzugriff (PDF)

Abstract P1-14-03: ABRAZO: Exposure-efficacy and -safety analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in a phase 2 open-label trial

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P1-P1-14-03

2018

Volltextzugriff (PDF)

Abstract P5-19-05: Health-related quality of life during a phase 2 study of talazoparib in patients with advanced breast cancer and germline BRCA1/2 mutations (ABRAZO)

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P5-P5-19-05

2018

Volltextzugriff (PDF)

Abstract P4-22-18: Phase Ib safety, efficacy, and molecular analysis of ribociclib (LEE011) plus letrozole for the treatment of ER+, HER2– advanced breast cancer

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P4-P4-22-18

2017

Volltextzugriff (PDF)

1 – 25 von 289

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(271)
Mit Volltextzugriff
(257)

Publikationsform

Sprache

Englisch
(288)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(140)
Life Sciences & Biomedicine
(130)
Humans
(78)
Female
(74)
Oncology
(64)
Biological And Medical Sciences
(61)
Animals
(60)
Medical Sciences
(49)
Breast Cancer
(48)
Breast Neoplasms - Drug Therapy
(44)
Male
(39)
Middle Aged
(39)
Adult
(30)
Aged
(28)
Breast Neoplasms - Pathology
(28)
Tumors
(28)
Chemotherapy
(27)
Rats
(23)
Gynecology. Andrology. Obstetrics
(20)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(19)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring

Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer

Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial

Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer

The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage

Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue

tAnGo : a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation

A phase II trial of low-dose estradiol in postmenopausal women with advanced breast cancer and acquired resistance to aromatase inhibition

FULVESTRANT: A REVIEW OF ITS DEVELOPMENT, PRE‐CLINICAL AND CLINICAL DATA

The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone

114PThe incidence of metastases detected on a staging CT scan prior to neoadjuvant chemotherapy in early stage breast cancer

The incidence of metastases detected on a staging CT scan prior to neoadjuvant chemotherapy in early stage breast cancer

198TiPA randomized, double-blinded, controlled study of tucatinib (ONT-380) vs placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB)

A quantitative histometric murine in vivo model of radiation-induced oral mucositis

A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB)

LBA23MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer (ABC)

Fatal Candida tropicalis fungaemia in a leukaemic patient receiving fluconazole prophylaxis

314PNext-generation DNA sequencing (NGS) results for tumours from phase II ABRAZO study of talazoparib after platinum or cytotoxic non-platinum regimens in patients (pts) with advanced breast cancer (ABC) and germline BRCA1/2 (gBRCA) mutations

Re: Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

Abstract P6-17-01: Withdrawn

Polymorphisms of the aromatase gene (CYP19A1) and benefit of aromatase inhibitors (AIs) in metastatic breast cancer (mBC) patients

Phase II data for entinostat, a class 1 selective histone deacetylase inhibitor, in patients whose breast cancer is progressing on aromatase inhibitor therapy

Abstract P1-14-03: ABRAZO: Exposure-efficacy and -safety analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in a phase 2 open-label trial

Abstract P5-19-05: Health-related quality of life during a phase 2 study of talazoparib in patients with advanced breast cancer and germline BRCA1/2 mutations (ABRAZO)

Abstract P4-22-18: Phase Ib safety, efficacy, and molecular analysis of ribociclib (LEE011) plus letrozole for the treatment of ER+, HER2– advanced breast cancer

Suchergebnisse filtern